Skip to main content

TuHURA Biosciences, Inc./NV

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

HURA$1.66+1.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

June 30,December 31,
20252024
(Unaudited)
Assets
Current Assets:
Cash and cash equivalents$8,512,824$12,657,178
Deposits, planned business acquisition (note 1)-5,994,503
Stock subsciption receivable2,997,547-
Other current assets1,029,088958,708
Total Current Assets12,539,45919,610,389
Property and equipment, net144,171123,366
Operating right-of-use assets122,511199,160
Other noncurrent assets-33,769
Goodwill13,554,163-
In-process research and development8,261,000-
Total Assets$34,621,304$19,966,684
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable and accrued expenses$12,093,163$5,170,166
Note Payable assumed from Kineta Merger434,000-
Holdback liability2,519,644-
Lease liabilities, current124,969159,844
Total Current Liabilities15,171,7765,330,010
Long-term Liabilities:
Lease liability, long term-42,698
Total Liabilities15,171,7765,372,708
Stockholders' Equity:
Preferred Stock Series A (assumed in Kintara merger); $1.00 par value, 278,530 shares outstanding as of June 30, 2025 and December 31, 2024278,530278,530
Common stock, $0.001 par value, 200,000,000 and 75,000,000 shares authorized; 49,913,946 and 42,323,759 shares issued and outstanding as of June 30, 2025 and December 31, 2024.49,91342,324
Additional paid in capital146,438,038125,397,691
Accumulated deficit(127,316,953)(111,124,569)
Total Stockholders' Equity19,449,52814,593,976
Total Liabilities and Stockholders' Equity$34,621,304$19,966,684
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.